Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical ...

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.